Apollo Proton Cancer Centre (APCC) and Ion Beam Applications (IBA), Belgium have signed an agreement to offer proton therapy training and education for clinicians in Asia and across the globe.
Apollo Hospitals has acquired IBA’s Proteus®PLUS proton therapy system and has been successfully treating cancer patients for over three years. Now, with this association, APCC will impart knowledge through its advanced training and education program on proton therapy to clinicians.
Announcing the partnership, Dr. Prathap C Reddy, Founder & Chairman, Apollo Hospitals Enterprise Ltd, said, “An acute need for high quality cancer care and the increasing prevalence of cancer cases in India, was the reason for the genesis of Apollo Cancer Centers (ACC), about three decades ago. Ever since, ACC has continually introduced the finest and most advanced cancer care into India, with the most recent being, bringing in Proton Therapy into the region. Furthermore, in keeping with its resolute mission to raise the bar in cancer care for all in need, in association with IBA, the Apollo Proton Cancer Centre is becoming the first of its kind training and education program reference center in Asia.”
Commenting on the collaboration, Mr. Olivier Legrain, Chief Executive Officer at IBA, said, “In the last few years, Apollo Hospitals has shown its expertise and motivation in organizing successful training symposia for local and international proton therapy experts’ community. We are looking forward to collaborating with Apollo to provide high-quality training and education to Proton Therapy users in Asia without need of traveling to another continent.”
Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Enterprise Ltd, said, “It was in 2019 that Proton Therapy was introduced at APCC, it was the first ever in South East Asia and Middle East and this was a definitive step ahead in making the world’s most advanced radiation therapy a lot more accessible to millions of cancer patients. Since then, in delivering care to hundreds of patients, the stellar teams at APCC have demonstrated remarkable expertise in Proton Therapy and the clinical outcomes underline the acumen. Now, with APCC becoming Asia’s first and exclusive Proton Beam Training Institute in association with IBA, it will provide valued access to clinicians across the world and also be a pivotal contributor to research in Oncology and Proton Therapy.”
Dr. Rakesh Jalali, Medical Director & Head of Radiation Oncology, Apollo Proton Cancer Centre, said, “We started the proton cancer center in India to provide the most advanced cancer treatment available in the world. So far, we have treated patients with various types of tumors. Each patient is selected based on a very intense and rigorous process and approved after discussion in a dedicated site-specific tumor board and peer review process. We have judiciously and consciously made the center on par with any other major international cancer center in terms of care, generation of quality data and several innovative educational initiatives. Now, with this collaboration, we’re providing access to clinicians, physicists and therapists from across Asia and the world to avail the opportunity for training and education on contemporary Proton Beam Therapy Practice.”
About IBA
IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.
